HIV and Viral Hepatitis Prevention, Treatment and Coinfection, 2nd Edition
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: 25 December 2025 | Viewed by 24
Special Issue Editors
Interests: hepatitis C virus; HIV; infectious diseases; virology; nanomedicine; neutralizing antibody
Special Issues, Collections and Topics in MDPI journals
Interests: HIV; hepatitis C; infectious diseases; immunology; virology; genetics; epidemiology; cirrhosis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hepatitis C is a disease caused by HCV that infects the liver and causes inflammation. According to the WHO, 58 million people worldwide live with chronic HCV infection and more than 350,000 people die each year from liver diseases related to this virus. Despite the extraordinary efficacy of direct-acting antivirals (DAAs) against HCV infection (with cure rates over 95%), there are still limitations that need to be addressed, including the lack of access to DAAs in marginalized and at-risk populations who are potential HCV transmitters, the emergence of multidrug resistance and reinfections.
On the other hand, HIV progressively attacks and weakens the immune system, destroys CD4 cells and ultimately leads to AIDS, increasing vulnerability to opportunistic infections. According to the WHO, 37.7 million people live with HIV and approximately 600,000 people die from HIV-related causes each year. Despite the great success of combined antiretroviral therapy, in the absence of an approved and effective vaccine, there is an urgent need to develop other alternative methods of pre-exposure prophylaxis.
As HCV and HIV share transmission routes, a large proportion of HCV-infected individuals are also coinfected with HIV. HIV/HCV coinfection increases the morbidity and mortality of patients with HIV due to the more aggressive progression of fibrosis and liver cirrhosis in coinfected individuals.
For this Special Issue, we invite contributors to submit research on discovering drugs with novel mechanisms of action, developing vaccines with the capacity to generate humoral immunity (for example, stimulating naive B cells in large populations to induce broadly neutralizing antibodies based on HIV Env or HCV E2) or different formulations (i.e., microbicides), to provide effective tools in the treatment, prevention, and eradication of these viruses.
Dr. Daniel Sepúlveda-Crespo
Dr. Salvador Resino
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- coinfection
- drug discovery
- HBV
- HCV
- HDV
- HIV
- neutralizing antibodies
- prevention
- treatment
- vaccine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
